ScienceDaily (Oct. 1, 2012) A novel therapy in the early stages of development at Virginia Commonwealth University Massey Cancer Center shows promise in providing lasting protection against the progression of multiple myeloma following a stem cell transplant by making the cancer cells easier targets for the immune system. Outlined in the British Journal of Hematology, the Phase II clinical trial was led by Amir Toor, M.D., hematologist-oncologist in the Bone Marrow Transplant Program and research member of the Developmental Therapeutics program at VCU Massey Cancer Center Continue reading
Tag Archives: investigational
Clinical trial for rabies monoclonal antibody
Public release date: 7-Aug-2012 [ | E-mail | Share ] Contact: Mark L. Shelton mark.shelton@umassmed.edu 508-856-2000 University of Massachusetts Medical School BOSTON, Mass. Continue reading
SalutarisMD Announces Positive Case Report of a New Investigational Wet AMD Therapy at ARVO
DENVER–(BUSINESS WIRE)– Positive results from a trial of episcleral brachytherapy to treat Wet Age-related Macular Degeneration (Wet AMD) were presented today at the ARVO Drug and Gene Delivery to the Back of the Eye Conference. The case reported was drawn from a Phase 1 study to assess the safety of this new investigational therapy for the leading cause of vision loss and blindness. Continue reading
UMass Medical School Enrolling Patients in Study of Tissue Expansion for Breast Reconstruction
WORCESTER, MA–(Marketwire -06/13/12)- The University of Massachusetts Medical School (UMMS) and UMass Memorial Medical Center have enrolled their first participant in a clinical study designed to evaluate a new tissue expansion method for breast reconstruction after a mastectomy. Continue reading
RetroSense Therapeutics Completes pre-IND Meeting for RST-001
ANN ARBOR, Mich.–(BUSINESS WIRE)– RetroSense Therapeutics, a gene therapy company dedicated to vision restoration, announced completion of a pre-IND meeting with the Center for Biological Evaluation and Research (CBER) division of the FDA that took place on May 22nd 2012 regarding RetroSenses lead biologic, RST-001 for vision restoration in retinal degenerative conditions. The purpose of the meeting was to obtain CBERs guidance for the clinical path to a Biologics License Application (BLA) for RST-001 in the US, and clarity on the steps required for Investigational New Drug (IND) submission. The discussions included manufacturing criteria, the scope and design of the preclinical studies, and the scope and design of Phase I and IIa clinical trials Continue reading